Literature DB >> 14523000

Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells.

Tomotoshi Marumoto1, Shinobu Honda, Toshihiro Hara, Masayuki Nitta, Toru Hirota, Eiji Kohmura, Hideyuki Saya.   

Abstract

Aurora-A, a member of the Aurora/Ipl1-related kinase family, is overexpressed in various types of cancer and considered to play critical roles in tumorigenesis. To better understand the pathological effect of Aurora-A activation, it is first necessary to elucidate the physiological functions of Aurora-A. Here, we have investigated the roles of Aurora-A in mitotic progression with the small interfering RNA, antibody microinjection, and time lapse microscopy using human cells. We demonstrated that suppression of Aurora-A by small interfering RNA caused multiple events to fail in mitosis, such as incorrect separation of centriole pairs, misalignment of chromosomes on the metaphase plate, and incomplete cytokinesis. Antibody microinjection of Aurora-A into late G2 cells induced dose-dependent failure in separation of centriole pairs at prophase, indicating that Aurora-A is essential for proper separation of centriole pairs. When we injected anti-Aurora-A antibodies into prometaphase cells that had separated their centriole pairs, chromosomes were severely misaligned on the metaphase plate, indicating that Aurora-A is required for proper movement of chromosomes on the metaphase plate. Furthermore, inhibition of Aurora-A at metaphase by microinjected antibodies prevented cells from completing cytokinesis, suggesting that Aurora-A also has important functions in late mitosis. These results strongly suggest that Aurora-A is essential for many crucial events during mitosis and that the phosphorylation of a series of substrates by Aurora-A at different stages of mitosis may promote diverse critical events in mitosis to maintain chromosome integrity in human cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523000     DOI: 10.1074/jbc.M306275200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  148 in total

1.  Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Authors:  Jodi A Muscal; Kathleen A Scorsone; Linna Zhang; Jeffrey A Ecsedy; Stacey L Berg
Journal:  Invest New Drugs       Date:  2012-06-06       Impact factor: 3.850

2.  Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Authors:  Gary K Schwartz; Richard D Carvajal; Rachel Midgley; Scott J Rodig; Paul K Stockman; Ozlem Ataman; David Wilson; Shampa Das; Geoffrey I Shapiro
Journal:  Invest New Drugs       Date:  2012-06-02       Impact factor: 3.850

3.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

4.  An integrated pharmacokinetic-pharmacodynamic model for an Aurora kinase inhibitor.

Authors:  Hiroko Kamei; Robert C Jackson; Daniella Zheleva; Fordyce A Davidson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-08-08       Impact factor: 2.745

5.  Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.

Authors:  Xiaofei Zhou; Sandeepraj Pusalkar; Swapan K Chowdhury; Shawn Searle; Yuexian Li; Claudio Dansky Ullmann; Karthik Venkatakrishnan
Journal:  Invest New Drugs       Date:  2018-11-06       Impact factor: 3.850

6.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

7.  Selection of cyclic-peptide inhibitors targeting Aurora kinase A: problems and solutions.

Authors:  Carolyn D Shomin; Elizabeth Restituyo; Kurt J Cox; Indraneel Ghosh
Journal:  Bioorg Med Chem       Date:  2011-09-29       Impact factor: 3.641

8.  Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts.

Authors:  Bedrick B Gadea; Joan V Ruderman
Journal:  Mol Biol Cell       Date:  2004-12-22       Impact factor: 4.138

9.  NDEL1 phosphorylation by Aurora-A kinase is essential for centrosomal maturation, separation, and TACC3 recruitment.

Authors:  Daisuke Mori; Yoshihisa Yano; Kazuhito Toyo-oka; Noriyuki Yoshida; Masami Yamada; Masami Muramatsu; Dongwei Zhang; Hideyuki Saya; Yoko Y Toyoshima; Kazuhisa Kinoshita; Anthony Wynshaw-Boris; Shinji Hirotsune
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

10.  The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells.

Authors:  Cory T Zumbar; Aisulu Usubalieva; Paul D King; Xiaohui Li; Caroline S Mifsud; Hailey M Dalton; Muge Sak; Sara Urio; William M Bryant; Joseph P McElroy; George Farmer; Norman L Lehman
Journal:  J Neurooncol       Date:  2018-02-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.